FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13s - 16 or 15d - 16 of
the Securities Exchange Act of 1934
For the month of January 2006
Acambis plc
(Translation of registrant's name into English)
Peterhouse Technology Park
100 Fulbourn Road
Cambridge CB1 9PT
England
(address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Forms 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information
contained in this Form also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934).
Yes No X
(if "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82- ).
Enclosures:
1. Blocklisting Interim Review
2. Holding(s) in Company
SCHEDULE 5
BLOCKLISTING SIX MONTHLY RETURN
1. Name of company
Acambis plc
2. Name of scheme
Acambis 1996 Approved Share Option Scheme
3. Period of return: From 01 July 2005 to 31 December 2005
4. Number and class of shares(s) (amount of stock/debt security) not issued
under scheme at end of last period:
370,069
5. Number of shares issued/allotted under scheme during period:
8,140
6. Balance under scheme not yet issued/allotted at end of period:
361,929
7. Number and class of share(s) (amount of stock/debt securities) originally
listed and the date of admission:
33,916,280 ordinary shares of 10p each
Date of admission: 30 November 1995
Please confirm total number of shares in issue at the end of the period in order
for us to update our records:
107,351,407
1. Name of company
Acambis plc
2. Name of scheme
Acambis 1995 Savings-Related Share Option Scheme
3. Period of return: From 01 July 2005 to 31 December 2005
4. Number and class of shares(s) (amount of stock/debt security) not issued
under scheme at end of last period:
84,690
5. Number of shares issued/allotted under scheme during period:
9,765
6. Balance under scheme not yet issued/allotted at end of period:
74,925
7. Number and class of share(s) (amount of stock/debt securities) originally
listed and the date of admission:
33,916,280 ordinary shares of 10p each
Date of admission: 30 November 1995
Please confirm total number of shares in issue at the end of the period in order
for us to update our records:
107,351,407
1. Name of company
Acambis plc
2. Name of scheme
Acambis 1999 Share Option Plan
3. Period of return: From 01 July 2005 to 31 December 2005
4. Number and class of shares(s) (amount of stock/debt security) not issued
under scheme at end of last period:
538,073
5. Number of shares issued/allotted under scheme during period:
4,000
6. Balance under scheme not yet issued/allotted at end of period:
534,073
7. Number and class of share(s) (amount of stock/debt securities) originally
listed and the date of admission:
33,916,280 ordinary shares of 10p each
Date of admission: 30 November 1995
Please confirm total number of shares in issue at the end of the period in order
for us to update our records:
107,351,407
1. Name of company
Acambis plc
2. Name of scheme
OraVax 1990 Stock Incentive Plan
3. Period of return: From 01 July 2005 to 31 December 2005
4. Number and class of shares(s) (amount of stock/debt security) not issued
under scheme at end of last period:
143,706
5. Number of shares issued/allotted under scheme during period:
Nil
6. Balance under scheme not yet issued/allotted at end of period:
143,706
7. Number and class of share(s) (amount of stock/debt securities) originally
listed and the date of admission:
33,916,280 ordinary shares of 10p each
Date of admission: 30 November 1995
Please confirm total number of shares in issue at the end of the period in order
for us to update our records:
107,351,407
1. Name of company
Acambis plc
2. Name of scheme
OraVax 1995 Stock Incentive Plan
3. Period of return: From 01 July 2005 to 31 December 2005
4. Number and class of shares(s) (amount of stock/debt security) not issued
under scheme at end of last period:
104,179
5. Number of shares issued/allotted under scheme during period:
Nil
6. Balance under scheme not yet issued/allotted at end of period:
104,179
7. Number and class of share(s) (amount of stock/debt securities) originally
listed and the date of admission:
33,916,280 ordinary shares of 10p each
Date of admission: 30 November 1995
Please confirm total number of shares in issue at the end of the period in order
for us to update our records:
107,351,407
Contact for queries: Elizabeth Brown
Address: Acambis plc, Peterhouse Technology Park, 100 Fulbourn Road, Cambridge
CB1 9PT
Name of person making return: Elizabeth Brown
Telephone: 01223 275300
Position of person making return: Company Secretary
Date of return: 9 January 2006
Holding in Company
Cambridge, UK and Cambridge, Massachusetts - 18 January 2006 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) announces an interest in its shares by The
Goldman Sachs Group, Inc.
On 16 January 2006, Acambis received notification that, as of the close of
business on 12 January 2006, The Goldman Sachs Group, Inc., ("GS Inc") of 85
Broad Street, New York, NY 10004, USA, was interested in a total of 4,258,375
ordinary shares of 10p each, representing a 3.97% holding of Acambis' issued
share capital.
Of these 4,258,375 shares:
a)the interest in 261,315 shares arose from an interest held
by Goldman, Sachs & Co. ("GS&Co."), a direct subsidiary of GS Inc., acting as
custodian; these shares are, or will be, registered in the name of Goldman Sachs
Securities (Nominees), Limited ("GSSN");
b)the interest in 625,400 shares arose from an interest held
by GS&Co, acting as custodian of 312,700 American Depositary Receipts ("ADRs");
these ADRs are, or will be, held at The Depositary Trust Company, New York;
c)the interest in 200 shares arose from a beneficial interest
in 100 ADRs held by GS&Co; these ADRs are, or will be, held at the DTC;
d)the interest in 47,630 shares arose from the interest held
by GS&Co., a direct subsidiary of GS Inc, acting as discretionary manager. These
shares are, or will be, registered in the name of GSSN; and
e)the interest in 3,323,830 shares arose from a beneficial
interest held by Goldman Sachs International, a direct subsidiary of GS Inc;
these shares are, or will be, registered at CREST in account CREPTEMP.
-ends-
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary: Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations: Tel: +44 (0) 1223 275
300
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis is establishing a travel vaccines
franchise through its US-based subsidiary Berna Products Corporation, which
markets Vivotif(R), the world's only licensed oral typhoid vaccine, in North
America. Acambis has other potential travel vaccines in development and is also
developing an investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last six years.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2004 Annual Report and "Risk factors" in the 2004 Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant Peptide Therapeutics Group has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Date: 31 January 2006 ACAMBIS PLC
By: /s/ Lyndsay Wright
Name: Lyndsay Wright
Title: VP, Communications and IR.